Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI-6110
- Development stage
- Preclinical
- Lead developer
- Avixgen
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
AVI-6110 is a preclinical drug candidate being developed by Avixgen for the treatment of wounds and the prevention of scarring. The drug is built upon the Avixgen Cell Penetrating (ACP) platform, a proprietary technology designed to enhance the intracellular delivery of therapeutic molecules. By utilizing this cell-penetrating conjugate, AVI-6110 aims to target biological pathways responsible for tissue regeneration and the fibrotic response. While the specific molecular target remains undisclosed, the candidate is positioned to improve healing outcomes and minimize the formation of scar tissue by delivering its therapeutic payload directly into the relevant cells at the site of injury.
Beyond the preview
Go deeper on AVI-6110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI-6110.